14th March
TriviumVet’s felycin®-CA1 has been granted conditional approval by the U.S. Food and Drug Administration (FDA). This marks a significant milestone in feline cardiac care as the...
Irish Veterinary R&D Pioneer TriviumVet Acquired by U.S. Group PBI-Gordon in Major International Milestone; Forms Strategic Alliance with Pegasus to Launch Innovative Veterinary Drug Portfolio
6th May
Waterford, Ireland – 6th May 2025— TriviumVet, the innovative Irish veterinary research and development company, has been acquired by U.S.-based PBI-Gordon Corporation, in a...
TriviumVet Secures FDA Conditional Approval for First Treatment for Feline Cardiac Disease
14th March
TriviumVet’s felycin®-CA1 has been granted conditional approval by the U.S. Food and Drug Administration (FDA). This marks a significant milestone in feline cardiac care as the...
TriviumVet’s Omeprazole product receives positive CVMP opinion.
20th February
On the 13th of February 2025, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion, recommendingthe granting of a marketing authorisation for the...
TriviumVet launch The REVERSE CKD Study recruiting cats with Chronic Kidney Disease (CKD)
7th February
We at TriviumVet received great excitement at this year's Feline Veterinary Medicine Association (formerly AAFP) conference on the work we have been doing in the area of CKD. We...
TriviumVet makes headway towards US approval of feline HCM therapy - S&P Global feature
22nd January
We were absolutely delighted to be featured in S&P Global last week in an article written by Joseph Harvey. See the article covering this exciting business update below.
TriviumVet launch the HALT HCM Study recruiting 300 cats with diagnosed subclinical Hypertrophic Cardiomyopathy (HCM)
25th June
We at TriviumVet are thrilled to announce that the long-awaited HALT HCM Study is now live and recruiting cats in cardiac care centers across the United States! The study was...
TriviumVet's Chief Scientific Officer, Dr. Stuart Fitzgerald appointed to NC State Industry Advisory Council
17th November
We are delighted to congratulate our Chief Scientific Officer, Dr. Stuart Fitzgerald on his appointment to this exciting new advisory council through which he will help to shape...
TriviumVet's Feline Chronic Kidney Disease (CKD) candidate deemed eligible for the Expanded Conditional Approval Pathway by the FDA!
10th October
FDA’s Centre for Veterinary Medicine deems TriviumVet’s feline Chronic Kidney Disease (CKD) therapeutic candidate eligible for the Expanded Conditional Approval pathway
TriviumVet are exhibiting at AAFP 2023!!
6th October
We are delighted to announce that we will be exhibiting at the American Association of Feline Practitioners conference 2023 taking place in Memphis, Tennessee next weekend. This...
Viewpoint With Dennis Quaid
26th September
The Cat is Out of the Bag!! Learn about the latest feline HCM research from scientists, researchers and cat owners. Viewpoint with Dennis Quaid and TriviumVet have teamed up to...
TriviumVet Secures FDA Conditional Approval for First Treatment for Feline Cardiac Disease
14th March
TriviumVet’s felycin®-CA1 has been granted conditional approval by the U.S. Food and Drug Administration (FDA). This marks a significant milestone in feline cardiac care as the...
TriviumVet’s Omeprazole product receives positive CVMP opinion.
20th February
On the 13th of February 2025, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion, recommendingthe granting of a marketing authorisation for the...
TriviumVet launch The REVERSE CKD Study recruiting cats with Chronic Kidney Disease (CKD)
7th February
We at TriviumVet received great excitement at this year's Feline Veterinary Medicine Association (formerly AAFP) conference on the work we have been doing in the area of CKD. We...
TriviumVet makes headway towards US approval of feline HCM therapy - S&P Global feature
22nd January
We were absolutely delighted to be featured in S&P Global last week in an article written by Joseph Harvey. See the article covering this exciting business update below.
TriviumVet launch the HALT HCM Study recruiting 300 cats with diagnosed subclinical Hypertrophic Cardiomyopathy (HCM)
25th June
We at TriviumVet are thrilled to announce that the long-awaited HALT HCM Study is now live and recruiting cats in cardiac care centers across the United States! The study was...
TriviumVet's Chief Scientific Officer, Dr. Stuart Fitzgerald appointed to NC State Industry Advisory Council
17th November
We are delighted to congratulate our Chief Scientific Officer, Dr. Stuart Fitzgerald on his appointment to this exciting new advisory council through which he will help to shape...
TriviumVet's Feline Chronic Kidney Disease (CKD) candidate deemed eligible for the Expanded Conditional Approval Pathway by the FDA!
10th October
FDA’s Centre for Veterinary Medicine deems TriviumVet’s feline Chronic Kidney Disease (CKD) therapeutic candidate eligible for the Expanded Conditional Approval pathway
TriviumVet are exhibiting at AAFP 2023!!
6th October
We are delighted to announce that we will be exhibiting at the American Association of Feline Practitioners conference 2023 taking place in Memphis, Tennessee next weekend. This...
Viewpoint With Dennis Quaid
26th September
The Cat is Out of the Bag!! Learn about the latest feline HCM research from scientists, researchers and cat owners. Viewpoint with Dennis Quaid and TriviumVet have teamed up to...